Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Indian J Pharmacol ; 55(5): 335-337, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37929413

RESUMO

Iron chelators have significantly reduced the morbidity associated with iron overload and improved the quality of life in children with beta-thalassemia major. A 5-year-old female child with beta-thalassemia major on recurrent transfusions and oral chelation with deferasirox was brought with repeated episodes of frank hematemesis and progressive lethargy. Her evaluation revealed anemia, leukocytosis, and deranged liver function with coagulopathy. She was given red blood cell and plasma transfusions with liver supportive medication and proton-pump inhibitor (PPI) infusion. Her upper gastrointestinal endoscopy revealed multiple ulcers in all three parts of the duodenum, which in the absence of any other likely etiology were attributed to prolonged use of oral deferasirox. The child improved with the above-mentioned measures. Chelation therapy was withheld for 2 weeks and restarted at a lower dose using enteric-coated preparation while PPIs were given for 8 weeks. She showed sustained improvement and remained well on follow-up.


Assuntos
Úlcera Duodenal , Choque Hemorrágico , Talassemia beta , Pré-Escolar , Feminino , Humanos , Talassemia beta/complicações , Talassemia beta/tratamento farmacológico , Deferasirox/efeitos adversos , Úlcera Duodenal/induzido quimicamente , Úlcera Duodenal/tratamento farmacológico , Quelantes de Ferro/efeitos adversos , Qualidade de Vida , Choque Hemorrágico/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...